Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt- treated uninephrectomized rats

Pharmazie

Volumn 66, Issue 9, 2011, Pages 716-719

  Guo, Peng ^a,c   Wu, Chongming ^b   Masaki, T ^c   Mori, H ^c   Nishiyama, A ^c  

^a INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

^b TSINGHUA UNIVERSITY   (China)

^c KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FASUDIL; MYOSIN; MYOSIN PHOSPHATASE TARGET SUBUNIT 1; PHOSPHATASE; RHO KINASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; NEPHRECTOMY; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; TREATMENT OUTCOME;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ALDOSTERONE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY WEIGHT; CALCIUM CHANNEL BLOCKERS; CARDIOMYOPATHIES; DNA PRIMERS; FIBROSIS; HEMODYNAMICS; HYPERTENSION; HYPERTENSION, RENAL; HYPERTROPHY, LEFT VENTRICULAR; MALE; NEPHRECTOMY; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SODIUM CHLORIDE;

EID: 84055194016     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.1524     Document Type: Article

References (32)

1. Chen XY, Dun JN, Miao QF, Zhang YJ (2009) Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway. Pharmacology 83: 67-79.
2. Connolly MJ, Aaronson PI (2011) Key role of the RhoA/Rho kinase system in pulmonary hypertension. Pulm Pharmacol Ther. 24: 1-14.
3. Dai ZK, Wu BN, Chen IC, Chai CY, Wu JR, Chou SH, Yeh JL, Chen IJ, Tan MS (2011) Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil. Pediatr Pulmonol 46: 45-59.
4. Demiryurek S, Kara AF, Celik A, Babul A, Tarakcioglu M, Demiryurek AT (2005) Effects of fasudil, a Rho-kinase inhibitor, on myocardial preconditioning in anesthetized rats. Eur J Pharmacol 527: 129-140. (Pubitemid 41745160)
5. Dong M, Yan BP, Liao JK, Lam YY, Yip GW, Yu CM (2010) Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today 15: 622-629.
6. Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG, McMurtry IF (2004) Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 287: L656-664. (Pubitemid 39249378)
7. Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, Shimokawa H (2010) Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 25: 144-149.
8. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Tawara S, Shinozaki T, KagayaY, ShimokawaH(2008) Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. J Cardiovasc Pharmacol 51: 317-326. (Pubitemid 351450612)
9. Fukumoto Y, Mohri M, Inokuchi K, Ito A, Hirakawa Y, Masumoto A, Hirooka Y, Takeshita A, Shimokawa H (2007) Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. J Cardiovasc Pharmacol 49: 117-121. (Pubitemid 46579944)
10. Funder JW (2010) Aldosterone, hypertension and heart failure: insights from clinical trials. Hypertens Res 33: 872-875.
11. Gradman AH, Wilson JT (2009) Hypertension and diastolic heart failure. Curr Cardiol Rep 11: 422-429.
12. Guo P, Nishiyama A, Rahman M, Nagai Y, Noma T, Namba T, Ishizawa M, Murakami K, Miyatake A, Kimura S, Mizushige K, Abe Y, Ohmori K, Kohno M (2006) Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade. J Hypertension 24: 1097-1104. (Pubitemid 43772318)
13. Haider AW, Larson MG, Franklin SS, Levy D (2003) Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 138: 10-16. (Pubitemid 36232089)
14. Hermida N, Lopez B, Gonzalez A, Dotor J, Lasarte JJ, Sarobe P, Borras- Cuesta F, Diez J (2009) A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res 81: 601-609.
15. Ho CY, Lopez B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, Kwong R, Gonzalez A, Colan SD, Seidman JG, Diez J, Seidman CE (2010) Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 363: 552-563.
16. Ishimaru K, Ueno H, Kagitani S, Takabayashi D, Takata M, Inoue H (2007) Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats. J Cardiovasc Pharmacol 50: 187-194. (Pubitemid 47267744)
17. Jiang BH, Tawara S, Abe K, Takaki A, Fukumoto Y, Shimokawa H (2007) Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 49: 85-89.
18. Koitabashi N, Arai M, Kogure S, Niwano K, Watanabe A, Aoki Y, Maeno T, Nishida T, Kubota S, Takigawa M, Kurabayashi M (2007) Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis. Hypertension 49: 1120-1127. (Pubitemid 351664300)
19. Lai A, Frishman WH (2005) Rho-kinase inhibition in the therapy of cardiovascular disease. Cardiol Rev 13: 285-292. (Pubitemid 41579592)
20. Lebrasseur NK, Duhaney TA, De Silva DS, Cui L, Ip PC, Joseph L, Sam F (2007) Effects of fenofibrate on cardiac remodeling in aldosteroneinduced hypertension. Hypertension 50: 489-496. (Pubitemid 47312234)
21. Li F, XiaW, Li A, Zhao C, Sun R (2007) Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats. Pharmacol Res 55: 64-71. (Pubitemid 46108589)
22. Li Y, Yao JH, Hu XW, Fan Z, Huang L, Jing HR, Liu KX, Tian XF (2011) Inhibition of Rho kinase by fasudil hydrochloride attenuates lung injury induced by intestinal ischemia and reperfusion. Life Sci 88: 104-109.
23. Mouchaers KT, Schalij I, de Boer MA, Postmus PE, van Hinsbergh VW, van Nieuw Amerongen GP, Vonk Noordegraaf A, van der Laarse WJ (2010) Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J 36: 800-807.
24. Otsuka T, Ibuki C, Suzuki T, Ishii K, Yoshida H, Kodani E, Kusama Y, Atarashi H, Kishida H, Takano T, Mizuno K (2008) Administration of the Rho-kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina. Coron Artery Dis 19: 105-110. (Pubitemid 351317374)
25. Pei Z, Meng R, Li G, Yan G, Xu C, Zhuang Z, Ren J, Wu Z (2010) Angiotensin-(1-7) ameliorates myocardial remodeling and interstitial fibrosis in spontaneous hypertension: role of MMPs/TIMPs. Toxicol Lett 199: 173-181.
26. Shichi D, Arimura T, Ishikawa T, Kimura A (2010) Heart-specific small subunit of myosin light chain phosphatase activates rho-associated kinase and regulates phosphorylation of myosin phosphatase target subunit 1. J Biol Chem 285: 33680-33690.
27. Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, Katagiri T, Yamauchi K, Yui Y, Minamino T, Nakashima M, Kato K (2002) Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 40: 751-761. (Pubitemid 36109293)
28. Shimokawa H, Takeshita A (2005) Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25: 1767-1775. (Pubitemid 41243442)
29. Simko F, Pechanova O (2010) Remodelling of the heart and vessels in experimental hypertension: advances in protection. J Hypertens 28 Suppl 1: S1-6.
30. Tourneux P, Chester M, Grover T, Abman SH (2008) Fasudil inhibits the myogenic response in the fetal pulmonary circulation.Am J Physiol Heart Circ Physiol 295: H1505-1513.
31. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S (1997) Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389: 990-994. (Pubitemid 27485693)
32. Wang YX, da Cunha V, Martin-McNulty B, Vincelette J, Li W, Choy DF, Halks-Miller M, Mahmoudi M, Schroeder M, Johns A, Light DR, Dole WP (2005) Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. Eur J Pharmacol 512: 215-222. (Pubitemid 40544356)